Dyslipidemia

Catch up on the most impactful headlines in dyslipidemia from all of 2025 with our Year in Review.

FDA approves lerodalcibep, a groundbreaking PCSK9 inhibitor, offering a monthly injection for LDL cholesterol reduction in patients with HoFH.

This FDA News Month in Review provides a round-up of regulatory decisions from November 2025.

Catch up with major FDA decisions, critical conference news, and more.

O’Donoghue discusses the results of this analysis of the FOURIER trial, highlighting that no limit was found for lowered LDL-C improving MACE risk.

O’Donoghue discusses the results of the recent OCEAN(a)-DOSE trial and addresses the implications for Lp(a)-lowering therapies moving forward.

Explore the critical role of nutrition and pharmacologic therapies in managing hypertriglyceridemia and preventing pancreatitis effectively.

Explore how the latest FDA approvals impact the management of FCS.

Panelists break down the potential role of plozasiran in FCS based on the PALISADE trial.

Understanding severe hypertriglyceridemia is crucial for preventing pancreatitis and managing triglyceride levels effectively.

Discover effective strategies to shorten the diagnostic window for pancreatitis and manage high triglyceride levels in FCS.

Explore the challenges and advancements in managing FCS with expert insights on treatment and patient care.

Stein discusses the results of a groundbreaking open-label extension, which indicates the efficacy and safety of this investigative oral PCSK9 inhibitor.

The FDA has approved RNA interference therapeutic plozasiran for the treatment of familial chylomicronemia syndrome.

Marston discusses the CORE and CORE2 trials, highlighting olezarsen’s success in lowering fasting triglyceride.

Data from 4 of the most impactful trials presented at the American Heart Association Scientific Sessions 2025.

Navar discusses the groundbreaking results of this phase 3 trial, as well as the implications of an oral PCSK9 inhibitor for treatment adherence and persistence.

This first-in-human phase 1 trial resulted in a groundbreaking reduction in both LDL cholesterol and triglycerides for the first time in history.

The investigative RNA-targeted antisense oligonucleotide achieved a reduction in fasting triglyceride of >72% in 6 months and sustained it through 12.

Adding evolocumab to existing lipid-lowering therapies significantly reduced first MACE risk, highlighting its efficacy in reducing cardiovascular mortality.

Alterations in appetite and weight may have influenced abdominal adiposity, as well as inflammatory and cardiometabolic markers.

This conference preview with Viet Le, DMSc, PA-C, for the 2025 AHA Scientific Sessions highlights the top 5 trials to watch.

A recent study highlights correlations between later healing, triglyceride levels, and total cholesterol in patients receiving MH.

A pooled cohort analysis of the phase 3 BROOKLYN and BROADWAY trials spotlighted obicetrapib’s impact on patients at risk of cardiovascular mortality.